Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03290079 |
|---|---|
| Brief Title: | Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors |
| First Submitted : | September 19, 2017 |
| First Submitted that Met QC Criteria : | September 19, 2017 |
| First Posted : | September 21, 2017 |
| Last Update Submitted that Met QC Criteria : | April 17, 2023 |
| Last Update Posted : | April 18, 2023 |